Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jun
03
Today In Oncology
Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases
Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo